Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a - A selective and direct factor Xa inhibitor

Journal of Thrombosis and Thrombolysis

Volumn 18, Issue 3, 2004, Pages 193-197

  Becker, Richard C ^a,b   Alexander, John H ^a,b   Li, You Fu ^c   Robertson, Thomas ^d   Kunitada, Satoshi ^d   Spencer, Frederick A ^c   Yang, Hongqiu ^b   Harrington, Robert A ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d DAIICHI SANKYO CO   (Japan)

Author keywords

Factor Xa inhibition; Tissue factor pathway inhibitor; Tissue factor VIIa complex; Vascular endothelial cells

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TISSUE CULTURE; UMBILICAL VEIN;

EID: 17644383683     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-0345-6     Document Type: Article

References (30)

1. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959-972.
2. Baugh RJ, Broze GJ, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998;273:4378-4386.
3. Lupu C, Goodwin CA, Westmuckett AD, et al. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/ caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997;17:2964-2974.
4. Ott I, Miyagi Y, Miyazaki K, et al. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinostol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000;20:874-882.
5. Hansen JB, Olsen R, Webster P. Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells. Blood 1997;90:3568-3578.
6. Dyke CK, Becker RC, Kleiman NS, et al. First experience with direct factor Xa inhibition in patients with stable coronary artery disease. A pharmacokinetic and pharmacodynamic evaluation. Circulation 2002;105:2385-2391.
7. Noteboom A, Hendrick S, Oheholler I, Vander Linden CJ. Permeability characteristics of human endothelial monolayers seeded on different extracellular matrix. Mediations of inflammation 2000;9:235-241.
8. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
9. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis. 1995;6(suppl 1):S7-S13.
10. Bonderman D, Temi A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002;99:2794-2800.
11. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor. Basic and Clinical Aspects. Arterioscler Thromb Vasc Biol 2002;22:539-548.
12. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91:619-622.
13. Sanders NL, Bajaj SP, Rapaport SI. A plasma protein that inhibits tissue factor-factor VII activation of factor IX in the presence of factor X. Circulation 1983;68(suppl):1266a.
14. Herman MP, Sukhova GK, Kisiel W, et al.Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinase with implications for atherosclerosis. J Clin Invest 2001;107:1117-1126.
15. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that the endothelium is the principle site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-8873.
16. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1995;15:2055-2062.
17. Hampton RY, Koning A, Wright R, Rine J. In vivo examination of membrane protein localization and degradation with green fluorescent protein. Proc Natl Acad Sci USA 1996;93:828-833. 10.1073/pnas.93.2.828
18. Simionescu M, Simionescu N. Endothelial transport of macromolecules: transcytosis and endocytosis. Cell Biol Rev 1991;25:1-80.
19. Sevinsky JR, Rao LVM, Ruf W. Ligand-induced protease receptor translocation in to caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996;133:293-304.
20. Morange PE, Simon C, Alessi MC, et al. PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease. The Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004;109:1343-1348.
21. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999;19:2251-2262.
22. Hansen J-B, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000;83:937-943.
23. Li Y, Rodriquez M, Spencer FA, Becker RC. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor inhibitor release: A model for assessing intrinsic thromboresistance. J Thromb Thrombolysis 2002;14:123-129.
24. Thréroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145.
25. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935.
26. Becker RC, Spencer FA, Li Y, et al. generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes. J Am Coll Card 1999;34:1020-1027.
27. Patton WA 2nd, Granzow CA, Getts LA, et al. Identification of a heparin binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells. Bio Chem J 1995;311:461-469.
28. Bono F, Herault JP, Avril C, Schaeffer P, Lormeau JC, Herbert JM. Human umbilical vein endothelial cells express high affinity receptors for factor Xa. J Cellular Physiol 1997;172:36-43.
29. Ho G, Toomey JR, Broze GJ Jr, Schwartz AL. Receptor-medicated endocytosis of coagulation factor Xa requires cell surface-bound tissue pathway inhibitor. J Biol Chem 1996;271:9497-9502.
30. Ho G, Toomey JR, Broze GJ Jr, Schwartz AL. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes. J Biol Chem 1997;272:16838-16844.